ELAB_OUT_1 [2025-03-20 09:39:55 -0400] 2747 Bytes | 719 tokens | Cum: 719 tkns (8.99% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at PMGC (ELAB) which is at 7.5239 up from 5.64. So, I pulled together a bunch of data for you to look over real fast. It's still early, 09:39:53 AM on Thursday March 20, 2025 ET (UTC-0400). So, what's the verdict? You're the expert!

Here's the first list of news for PMGC:

C1 - Mar-10-25 08:00AM - Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1
C2 - Mar-06-25 09:00AM - PMGC Holdings Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance
C3 - Feb-27-25 08:00AM - PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group
C4 - Feb-26-25 08:30AM - PMGC Holdings Highlights Strong Capital Position: No Debt, Fully Funded, and Warrants Priced Above Market
C5 - Feb-18-25 07:00AM - Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Announces Successful Submission of Pre-IND Meeting Request to FDA for EL-22, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 Receptor Agonists
C6 - Feb-04-25 08:00AM - Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1
C7 - Jan-31-25 10:33AM - PMGC Capital LLC, a subsidiary of PMGC Holdings Inc., Begins to Build Portfolio with Strategic Acquisition of shares in U.S.-Focused Uranium Energy and Fire Prevention Technology Companies
C8 - Jan-30-25 08:00AM - Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on PMGC (ELAB)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

ELAB_OUT_3 [2025-03-20 09:39:58 -0400] 996 Bytes | 315 tokens | Cum: 1036 tkns (12.95% of 8k)
==========================================================================

Showing C1 (chunk 1 of 7): C1:
**Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1**
Date: Mar-10-25 08:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/10/3039692/0/en/Northstrive-Biosciences-Inc-Schedules-Pre-IND-Meeting-with-FDA-for-EL-22-an-Obesity-Therapy-Targeting-Fat-Loss-and-Muscle-Preservation-in-Combination-with-GLP-1.html

March 10, 2025 08:00 ET| Source:PMGC Holdings Inc.PMGC Holdings Inc.

NEWPORT BEACH, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), announced that it has scheduled a pre-Investigational New Drug (“pre-IND”) meeting with the U.S. Food and Drug Administration (“FDA”) for Wednesday, April 23, 2025. Northstriv

-- More? (MOR) or Next section? (NEX)

ELAB_OUT_5 [2025-03-20 09:39:59 -0400] 939 Bytes | 279 tokens | Cum: 1318 tkns (16.48% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-10T15:36:42Z - PMGC Holdings Stock Drops 7%...
A2 - 2025-03-10T12:20:36Z - Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Target...
A3 - 2025-03-10T12:16:19Z - Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Target...
A4 - 2025-03-10T12:02:49Z - Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy ......
A5 - 2025-03-10T12:05:05Z - Northstrive sets FDA pre-IND meeting for obesity treatment By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ELAB_OUT_7 [2025-03-20 09:40:11 -0400] 967 Bytes | 268 tokens | Cum: 1588 tkns (19.85% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**PMGC Holdings Stock Drops 7%**Date: 2025-03-10Source: {'uri': 'rttnews.com', 'dataType': 'news', 'title': 'RTTNews'}URL: https://www.rttnews.com/3520141/pmgc-holdings-stock-drops-7.aspxShares of PMGC Holdings Inc. (ELAB) are dropping about 7 percent during Monday's trading, following an announcement made by its subsidiary Northstrive Biosciences Inc. regarding the EL-22 as a combination treatment with GLP-1 for muscle preservation.

The subsidiary stated that it has scheduled a Type-B pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on April 23, 2025.

Currently, PMGC's stock is trading at 7.52 percent, down $4.65 on the Nasdaq. It has traded between $4.39 to $1,161.72 in the past one year.

Upon FDA feedback and guidance, Northstrive aims to file the IND application in 2025 and thereafter initiate clinical trials to evaluate the combination of EL-22

-- More? (MOR) or Next section? (NEX)

ELAB_OUT_9 [2025-03-20 09:40:12 -0400] 951 Bytes | 301 tokens | Cum: 2051 tkns (25.64% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-28T22:00:00Z - Univest Securities, LLC Announces Closing of $1.92 Million Warrant Inducement for its Client PMGC Holdings Inc. (NASDAQ: ELAB)
B2 - 2025-01-27T14:00:00Z - PMGC Holdings Inc. Announces $1.9 Million in Gross Proceeds from Warrant Inducement with Institutional Investors
B3 - 2025-01-02T20:55:00Z - PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy
B4 - 2024-11-22T22:00:00Z - Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess
B5 - 2024-11-14T19:35:00Z - CORRECTION - Elevai Labs Inc.
B6 - 2024-11-04T22:45:00Z - Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ELAB_OUT_11 [2025-03-20 09:40:18 -0400] 831 Bytes | 226 tokens | Cum: 2279 tkns (28.49% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Univest Securities, LLC Announces Closing of $1.92 Million Warrant Inducement for its Client PMGC Holdings Inc. (NASDAQ: ELAB)**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/28/3016810/0/en/Univest-Securities-LLC-Announces-Closing-of-1-92-Million-Warrant-Inducement-for-its-Client-PMGC-Holdings-Inc-NASDAQ-ELAB.htmlUnivest Securities, LLC announced the completion of a warrant inducement with existing institutional investors for its client PMGC Holdings Inc. (NASDAQ: ELAB), a diversified holding company. The investors agreed to exercise outstanding warrants to purchase 969,386 shares of PMGC's common stock at an amended exercise price of $2.00, generating gross proceeds of approximately $1.9 million.

-- More? (MOR) or Next section? (NEX)

ELAB_OUT_13 [2025-03-20 09:40:19 -0400] 1160 Bytes | 331 tokens | Cum: 2703 tkns (33.79% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S1 - 2025-02-27 8-K Item 9.01. Fin Stmnts and Exhibits.

(d) Exhibits.

Exhibit No. Description 3.1 Amended and Restated Certificate of Designations, Rights, and Preferences of Series B Preferred Stock, filed with the Secretary of State of the State of Nevada on February 21, 2025. 3.2 Ce...

S2 - 2025-02-27 8-K Item 9.01. Fin Stmnts and Exhibits.

(d) Exhibits.

Exhibit No. Description 3.1 Amended and Restated Certificate of Designations, Rights, and Preferences of Series B Preferred Stock, filed with the Secretary of State of the State of Nevada on February 21, 2025. 3.2 Ce...

S3 - 2025-02-19 8-K Item 7.01 Regulation FD Disclosure

On February 18, 2025, Northstrive Biosciences Inc. (Northstrive Biosciences), a subsidiary of PMGC Holdings Inc. (the Company), i ssued a press release announcing its submission of a pre-Investigational New Drug meeting request to the U.S. Foo...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

ELAB_OUT_15 [2025-03-20 09:40:25 -0400] 647 Bytes | 163 tokens | Cum: 2868 tkns (35.85% of 8k)
==========================================================================

Showing S2 (chunk 1 of 1): S2:
Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description 3.1 Amended and Restated Certificate of Designations, Rights, and Preferences of Series B Preferred Stock, filed with the Secretary of State of the State of Nevada on February 21, 2025. 3.2 Certificate of Amendment to the Amended and Restated Certificate of Designations, Rights, and Preferences of Series B Preferred Stock, filed with the Secretary of State of the State of Nevada on February 24, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)...

-- More? (MOR) or Next section? (NEX)

ELAB_OUT_17 [2025-03-20 09:40:45 -0400] 4321 Bytes | 1227 tokens | Cum: 4184 tkns (52.30% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+----------------------+------------------------+--------------------------+-------------------+
| Volume: 0 | SMA50: -48.95% | Market Cap: 3.26M | Option/Short: No / Yes | Sales past 5Y: 46340.47% | Sales Surprise: - |
+---------------------+-----------------------+----------------------+------------------------+--------------------------+-------------------+
| Avg Volume: 267.31K | SMA200: -97.90% | Shs Outstand: 0.58M | Short Float: 3.41% | Employees: 18 | EPS Surprise: - |
+---------------------+-----------------------+----------------------+------------------------+--------------------------+-------------------+
| Rel Volume: 0.00 | Perf Week: 37.23% | Shs Float: 0.57M | Short Ratio: 0.07 | Debt/Eq: 0.01 | P/E: - |
+---------------------+-----------------------+----------------------+------------------------+--------------------------+-------------------+
| RSI (14): 35.93 | Perf Month: -51.46% | Inst Own: 1.06% | Short Interest: 0.02M | Sales Y/Y TTM: - | Earnings: - |
+---------------------+-----------------------+----------------------+------------------------+--------------------------+-------------------+
| ATR (14): 1.20 | Perf Quarter: -64.82% | Insider Own: 0.92% | Beta: -1.92 | ROE: -130.35% | |
+---------------------+-----------------------+----------------------+------------------------+--------------------------+-------------------+
| SMA20: -19.69% | Index: - | Insider Trans: 0.00% | Sales Q/Q: -4.90% | ROI: -63.92% | |
+---------------------+-----------------------+----------------------+------------------------+--------------------------+-------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Now we've reached the end of the analysis.
You are now invited to make a summary analysis.
Please don't explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.
Please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]
Again, that is: 1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

[Company Financial Summary]
[Company Details]
Name: PMGC Holdings Inc. Common Stock
Market Cap: 3254280.0
Shares Outstanding: 577000
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 2446161.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -5468914.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 7.75
Average Volume: 90203.5
30-Day High: 11.9
30-Day Low: 3.92

[Detailed Financials: Q3 2024]
- Total Assets: $11,205,355.0
- Total Liabilities: $2,650,133.0
- Total Equity: $8,555,222.0
- Current Assets: $8,227,826.0
- Current Liabilities: $2,130,422.0

[Income Statement: Q3 2024]
- Revenue: $527,478
- Net Income: $-1,501,257.0
- Operating Income: $-919,837
- Earnings Per Share (EPS): -0.068

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $3,098,239.0

[Detailed Financials: Q2 2024]
- Total Assets: $5,080,221.0
- Total Liabilities: $2,440,585.0
- Total Equity: $2,639,636.0
- Current Assets: $2,031,096.0
- Current Liabilities: $1,935,224.0

[Income Statement: Q2 2024]
- Revenue: $605,529
- Net Income: $-1,412,491.0
- Operating Income: $-1,408,613.0
- Earnings Per Share (EPS): -0.08

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $754
==== END OF FINANCIAL REPORT ====

ELAB_OUT_19 [2025-03-20 09:40:47 -0400] 561 Bytes | 131 tokens | Cum: 4641 tkns (58.01% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings & insider data
-> X3 <- Broader sector & market news
-> X4 <- General market sentiment & AI confidence levels
-> X5 <- AI's past analysis on similar companies
-> X6 <- More financial metrics
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

ELAB_IN_21 [2025-03-20 09:40:48 -0400] 126 Bytes | 29 tokens | Cum: 4677 tkns (58.46% of 8k)
==========================================================================

====================================
[2025-03-20 06:40:48] # Analysis Completed
Elapsed Time: 55.10 seconds